Kai Tan

ORCID: 0000-0001-6081-2543
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Blood Pressure and Hypertension Studies
  • Computational Drug Discovery Methods
  • Eicosanoids and Hypertension Pharmacology
  • Pharmacogenetics and Drug Metabolism
  • Gout, Hyperuricemia, Uric Acid
  • Inflammasome and immune disorders
  • Peptidase Inhibition and Analysis
  • Health Systems, Economic Evaluations, Quality of Life
  • Atrial Fibrillation Management and Outcomes

Qingdao University
2020-2021

Affiliated Hospital of Qingdao University
2020-2021

BACKGROUNDThe quality of warfarin therapy can be determined by the time in therapeutic range (TTR) international normalized ratio (INR).The estimated minimum TTR needed to achieve a benefit from is ≥ 60%. AIMTo determine and predictors poor among atrial fibrillation patients who receive therapy. METHODSA retrospective observational study was conducted at cardiology referral center Selangor, Malaysia.A total 420 with under follow-up pharmacist led Warfarin Medication Therapeutic Adherence...

10.4330/wjc.v13.i9.483 article EN World Journal of Cardiology 2021-09-18

To compare the accuracy of five warfarin-dosing algorithms and warfarin stable dose model (2.5 mg/day) for Shandong population.One hundred twenty patients who achieved were enrolled. Clinical genetic data used to evaluate value each algorithm by calculating percentage whose predicted was within 20% actual therapeutic mean absolute error (MAE).The frequency with CYP2C9*1/*1, CYP2C9*1/*3 CYP2C9*1/*2 genotype 92.00%, 7.20%, 0.80%, respectively. That VKORC1-1639 AA, AG GG 82.40%, 15.20%, 2.40%,...

10.3760/cma.j.issn.1003-9406.2020.04.009 article EN PubMed 2020-04-10
Coming Soon ...